Email this article 
Circulating tumor DNA detection (liquid biopsy): prospects in oncology
- Authors: Zhukov N.V.1,2,3, Zaretskiy A.R.4,5,6, Lukyanov S.A.4,5,6, Rumyantsev S.A.1,2,3
-
Affiliations:
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow
- 1, Ostrovityanova st., Moscow, Russia, 117997 Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow
- 1, Samory Mashela st., Moscow, Russia, 117198
- Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow
- 1, Samory Mashela st., Moscow, Russia, 117198 M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow
- 16/10, Miklukho-Maklaya st., Moscow, Russia, 117198
- Issue: Vol 9, No 4 (2014)
- Pages: 28-36
- Section: BASIC RESEARCH
- Published: 30.12.2014
- URL: https://oncohematology.abvpress.ru/ongm/article/view/129
- DOI: https://doi.org/10.17650/1818-8346-2014-9-4-28-36
- ID: 129
Cite item
Full Text
Abstract
Modern research techniques allows tumor studying in almost any level: protein expression, structural changes of DNA, RNA, epigenetic changes, activity of signaling pathways, microenvironment, interaction with the immune system, etc. However, tumor samples are obtained as 100 years ago – by tumor biopsy prior to treatment. Based on available data about intratumoral heterogeneity and tumor changes during treatment, it may be one of the factors braking to obtain required information of tumor biology. According to study, the analysis of circulating tumor DNA (ctDNA) allows to hope to overcome the key limitations of routine biopsy. One of the key benefits of ctDNA analysis is the ability to a more comprehensive tumor investigation, while maintaining a high level of specificity, almost as well as a routine biopsy. Detection sensitivity of ctDNA continues to increase due to the development of new technology. The study of ctDNA may lead to breakthrough results in understanding of tumors molecular heterogeneity, development of resistance to anticancer therapy and ways to overcome it, screening and a number of other key areas of modern oncology.
About the authors
N. V. Zhukov
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 1, Ostrovityanova st., Moscow, Russia, 117997Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1, Samory Mashela st., Moscow, Russia, 117198
Author for correspondence.
Email: zhukov.nikolay@rambler.ru
Russian Federation
A. R. Zaretskiy
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1, Samory Mashela st., Moscow, Russia, 117198M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow; 16/10, Miklukho-Maklaya st., Moscow, Russia, 117198
Russian Federation
S. A. Lukyanov
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1, Samory Mashela st., Moscow, Russia, 117198M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow; 16/10, Miklukho-Maklaya st., Moscow, Russia, 117198
Russian Federation
S. A. Rumyantsev
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia, Moscow; 1, Ostrovityanova st., Moscow, Russia, 117997Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia, Moscow; 1, Samory Mashela st., Moscow, Russia, 117198
Russian Federation
References
Supplementary files
